Mediolanum International Funds Ltd Acquires 9,969 Shares of Axon Enterprise, Inc $AXON

Mediolanum International Funds Ltd lifted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 332.5% in the second quarter, Holdings Channel.com reports. The fund owned 12,967 shares of the biotechnology company’s stock after purchasing an additional 9,969 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Axon Enterprise were worth $10,615,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AXON. Vanguard Group Inc. lifted its stake in Axon Enterprise by 3.5% during the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock worth $7,399,515,000 after purchasing an additional 305,252 shares during the period. Geode Capital Management LLC grew its stake in shares of Axon Enterprise by 5.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after purchasing an additional 115,349 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after buying an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Axon Enterprise by 1.2% during the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after buying an additional 8,794 shares during the period. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AXON shares. Raymond James Financial reiterated an “outperform” rating and issued a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Bank of America lifted their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Barclays lowered their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Wednesday. Finally, Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a report on Tuesday, August 5th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $814.00.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $521.99 on Friday. The business has a fifty day moving average of $681.33 and a 200-day moving average of $731.06. The firm has a market cap of $41.19 billion, a PE ratio of 128.89, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same period in the prior year, the firm posted $1.45 earnings per share. The company’s revenue was up 30.6% on a year-over-year basis. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares in the company, valued at $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeri Williams sold 100 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the transaction, the director owned 1,416 shares in the company, valued at approximately $1,065,596.64. This represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 38,622 shares of company stock worth $26,439,364 in the last quarter. 4.40% of the stock is owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.